FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COUGHLIN CHRISTOPHER J		 2. Issuer Name and Ticker or Trading Symbol

ALEXION PHARMACEUTICALS, INC. [ ALXN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ALEXION PHARMACEUTICALS, INC, 121 SEAPORT BOULEVARD		 3. Date of Earliest Transaction (MM/DD/YYYY)

7/21/2021
(Street)

BOSTON, MA 02210
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $.0001 per share 7/21/2021  D  42347 (1)D$0 0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock $138.86 7/21/2021  D     2294  5/11/2017 (2)5/11/2026 Common Stock, par value $.0001 per share 2294.0 $138.86 0 D  
Option to Purchase Common Stock $167.97 7/21/2021  D     2706  7/22/2015 (2)7/22/2024 Common Stock, par value $.0001 per share 2706.0 $167.97 0 D  
Option to Purchase Common Stock $155.01 7/21/2021  D     2343  5/6/2016 (2)5/6/2025 Common Stock, par value $.0001 per share 2343.0 $155.01 0 D  
Explanation of Responses:
(1) Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
(2) Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
COUGHLIN CHRISTOPHER J
C/O ALEXION PHARMACEUTICALS, INC
121 SEAPORT BOULEVARD
BOSTON, MA 02210		X
Signatures
/s/ Douglas Barry, Attorney-in-Fact for Christopher J. Coughlin.7/23/2021
**Signature of Reporting PersonDate
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Alexion Pharmaceuticals Charts.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Alexion Pharmaceuticals Charts.